多粘菌素,多肽抗生素,来源于多粘菌的培养物,于1950年代引入并用于临床实践,但由于其肾毒性而被更安全的抗菌药物所取代。近年来,随着多药耐药(MDR)和广泛耐药(XDR)杆菌感染发生率的增加,多粘菌素被重新引入临床,因为它在MDR感染和XDR感染的治疗中起着重要作用。为了规范多粘菌素的临床应用,我们组织相关领域的专家制定了多粘菌素的专家共识,以供参考,包括药代动力学和药效学等参数,剂量和用法,禁忌症和相对禁忌症,临床应用及不良反应。
Polymyxin, a polypeptide antibiotic, derived from the culture of bacillus polymucilis, was introduced in the 1950s and used in clinical practice, but was replaced by safer antimicrobials due to its renal toxicity. In the recent years, with the increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacilli infections, polymyxin is reintroduced into the clinic because it is assumed an important role in the treatment of MDR infections and XDR infections. In order to regulate the clinical applications of polymyxin, we organized experts in relevant fields to develop expert
consensus on polymyxin for reference, including parameters like pharmacokinetics and pharmacodynamics, dosage and usage, contraindications and relative contraindications, clinical applications and adverse reactions.